113 related articles for article (PubMed ID: 15210850)
1. Interstitial gene delivery in human xenograft prostate tumors using titanium metal seeds.
Jung M; Zhang Y; Dimtchev A; Subramanian MR; Suthanthiran K; Dritschilo A
Mol Cancer Ther; 2004 Jun; 3(6):655-9. PubMed ID: 15210850
[TBL] [Abstract][Full Text] [Related]
2. Combining radiation therapy with interstitial radiation-inducible TNF-α expression for locoregional cancer treatment.
Jung M; Dimtchev A; Velena A; Dritschilo A
Cancer Gene Ther; 2011 Mar; 18(3):189-95. PubMed ID: 21052099
[TBL] [Abstract][Full Text] [Related]
3. Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model.
Siemens DR; Austin JC; Hedican SP; Tartaglia J; Ratliff TL
J Natl Cancer Inst; 2000 Mar; 92(5):403-12. PubMed ID: 10699070
[TBL] [Abstract][Full Text] [Related]
4. CWR22 xenograft as an ex vivo human tumor model for prostate cancer gene therapy.
Cheng L; Sun J; Pretlow TG; Culp J; Yang NS
J Natl Cancer Inst; 1996 May; 88(9):607-11. PubMed ID: 8609662
[TBL] [Abstract][Full Text] [Related]
5. p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy.
Seki M; Iwakawa J; Cheng H; Cheng PW
Hum Gene Ther; 2002 Apr; 13(6):761-73. PubMed ID: 11936974
[TBL] [Abstract][Full Text] [Related]
6. Nonviral in vivo gene delivery into tumors using a novel low volume jet-injection technology.
Walther W; Stein U; Fichtner I; Malcherek L; Lemm M; Schlag PM
Gene Ther; 2001 Feb; 8(3):173-80. PubMed ID: 11313788
[TBL] [Abstract][Full Text] [Related]
7. Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth.
Watanabe M; Nasu Y; Kashiwakura Y; Kusumi N; Tamayose K; Nagai A; Sasano T; Shimada T; Daida H; Kumon H
Hum Gene Ther; 2005 Jun; 16(6):699-710. PubMed ID: 15960601
[TBL] [Abstract][Full Text] [Related]
8. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy.
Jin F; Xie Z; Kuo CJ; Chung LW; Hsieh CL
Cancer Gene Ther; 2005 Mar; 12(3):257-67. PubMed ID: 15565180
[TBL] [Abstract][Full Text] [Related]
9. Microbubble-assisted p53, RB, and p130 gene transfer in combination with radiation therapy in prostate cancer.
Nande R; Greco A; Gossman MS; Lopez JP; Claudio L; Salvatore M; Brunetti A; Denvir J; Howard CM; Claudio PP
Curr Gene Ther; 2013 Jun; 13(3):163-74. PubMed ID: 23531191
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector.
Iyer M; Salazar FB; Lewis X; Zhang L; Carey M; Wu L; Gambhir SS
Mol Ther; 2004 Sep; 10(3):545-52. PubMed ID: 15336654
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer.
Kaliberov SA; Kaliberova LN; Stockard CR; Grizzle WE; Buchsbaum DJ
Mol Ther; 2004 Dec; 10(6):1059-70. PubMed ID: 15564138
[TBL] [Abstract][Full Text] [Related]
12. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A.
Zheng JY; Chen D; Chan J; Yu D; Ko E; Pang S
Cancer Gene Ther; 2003 Oct; 10(10):764-70. PubMed ID: 14502229
[TBL] [Abstract][Full Text] [Related]
13. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer.
Kawakami K; Kawakami M; Puri RK
J Immunol; 2002 Dec; 169(12):7119-26. PubMed ID: 12471149
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model.
Raikwar SP; Temm CJ; Raikwar NS; Kao C; Molitoris BA; Gardner TA
Mol Ther; 2005 Dec; 12(6):1091-100. PubMed ID: 16169279
[TBL] [Abstract][Full Text] [Related]
15. Systemic dissemination of viral vectors during intratumoral injection.
Wang Y; Hu JK; Krol A; Li YP; Li CY; Yuan F
Mol Cancer Ther; 2003 Nov; 2(11):1233-42. PubMed ID: 14617797
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus p16 gene therapy for prostate cancer.
Allay JA; Steiner MS; Zhang Y; Reed CP; Cockroft J; Lu Y
World J Urol; 2000 Apr; 18(2):111-20. PubMed ID: 10854145
[TBL] [Abstract][Full Text] [Related]
17. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
18. Experimental treatment of ovarian cancers by adenovirus vectors combining receptor targeting and selective expression of tumor necrosis factor.
Murugesan SR; Akiyama M; Einfeld DA; Wickham TJ; King CR
Int J Oncol; 2007 Oct; 31(4):813-22. PubMed ID: 17786312
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence.
Steiner MS; Zhang Y; Farooq F; Lerner J; Wang Y; Lu Y
Cancer Gene Ther; 2000 Mar; 7(3):360-72. PubMed ID: 10766342
[TBL] [Abstract][Full Text] [Related]
20. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth.
Kawakita M; Rao GS; Ritchey JK; Ornstein DK; Hudson MA; Tartaglia J; Paoletti E; Humphrey PA; Harmon TJ; Ratliff TL
J Natl Cancer Inst; 1997 Mar; 89(6):428-36. PubMed ID: 9091644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
